While many cancer therapies initially can be very successful, tumours often return and spread when remaining cancer cells develop resistance to treatment.
To combat this tendency, Frédéric Thomas of the French National Centre for Scientific Research proposes that cancer researchers take a lesson from our own immune system and explore "natural adaptive therapies."
Such an approach would mimic the immune system's more restrained way of keeping cancer in check by gradually killing off cancerous cells. Ideally, these therapies would remove the evolutionary pressure that often leads to the spread of resistant tumours.
In Thomas' article, published in the open access journal PLOS Biology, he and his colleagues reason that the body has evolved anti-cancer responses that direct and slow the evolution of life-threatening cancer cells by not killing off too many cells too quickly.
Natural adaptive therapies would use a similar approach to keep tumour size stable, while slowing the evolution of resistance.
This strategy may be especially useful to prolong lifespan and quality of life in patients after a cancer has metastasized.
The authors also explore the risk that cancer immunotherapies may force the immune system to rapidly kill malignant cells in a way that undermines the body's natural adaptive therapies, thus accelerating the evolution of immune resistance.
According to Thomas, further explorations into the mechanisms employed by the immune system to stabilize tumours could help researchers to identify new therapies to prevent tumour growth and metastasis.
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.